Photo of Matthew Hiram Taylor, M.D.

Matthew Hiram Taylor M.D.

Dr. Taylor runs the phase I clinical trials program for adults with advanced solid tumor malignancies. He also specializes in treating patients with metastatic melanoma and thyroid cancer.

Education

  • M.D., Oregon Health & Science University, Portland Oregon 2005
  • Residency:

    • Internal medicine, University of Washington, 2007
  • Fellowship:

    • Hematology and medical oncology, Oregon Health & Science University, 2010
  • Certifications:

    • American Board of Internal Medicine, 2009

Memberships and associations

  • American College of Physicians

Publications

  • "Signature program : A platform of basket trials." Oncotarget  In: , Vol. 9, No. 30, 20.04.2018, p. 21383-21395.
  • "Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor) : pooled results from two expansion cohorts of an open-label, phase 1 trial." The Lancet Oncology In: , Vol. 19, No. 1, 01.01.2018, p. 51-64.
  • "Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC) : A phase 1b open-label study." American Journal of Hematology  In: , 01.01.2018.
  • "Safety profile of avelumab in patients with advanced solid tumors : A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials." Cancer In: , 01.01.2018.
  • "Defining Radioiodine-Refractory Differentiated Thyroid Cancer : Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial." Thyroid : official journal of the American Thyroid Association  In: , Vol. 27, No. 9, 01.09.2017, p. 1135-1141.
  • "Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors." Journal of Clinical Oncology  In: , Vol. 35, No. 18, 20.06.2017, p. 2028-2036.
  • "Academic cancer center phase i program development." Oncologist In: , Vol. 22, No. 4, 01.04.2017, p. 369-374.
  • "Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer." Journal of Clinical Endocrinology and Metabolism  In: , Vol. 101, No. 11, 01.11.2016, p. 4103-4109.
  • "Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma : 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial." The Lancet Oncology In: , Vol. 17, No. 11, 01.11.2016, p. 1558-1568.
  • "Open-label, multicenter, phase 1 study of alisertib (MLN8237), an aurora A kinase inhibitor, with docetaxel in patients with solid tumors." Cancer  In: , Vol. 122, No. 16, 15.08.2016, p. 2524-2533.
  • "Treatment patterns, health state, and health care resource utilization of patients with radioactive iodine refractory differentiated thyroid cancer." Cancer Management and Research In: , Vol. 8, 30.05.2016, p. 67-76.
  • "Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032) : A multicentre, open-label, phase 1/2 trial." The Lancet Oncology  In: , 2016.
  • "Fibroblast Growth Factor Signaling Controls Liver Size in Mice with Humanized Livers." Gastroenterology  In: , Vol. 149, No. 3, 01.09.2015, p. 728e15-740e15.
  • "Nivolumab and ipilimumab versus ipilimumab in untreated melanoma." New England Journal of Medicine  In: , Vol. 372, No. 21, 21.05.2015, p. 2006-2017.
  • "Lenvatinib versus placebo in radioiodine-refractory thyroid cancer." New England Journal of Medicine In: , Vol. 372, No. 7, 12.02.2015, p. 621-630.
  • "Medical Therapy for Advanced Forms of Thyroid Cancer." Surgical Clinics of North America  In: , Vol. 94, No. 3, 2014, p. 541-571.
  • "The ploidy conveyor of mature hepatocytes as a source of genetic variation." Nature  In: , Vol. 467, No. 7316, 07.10.2010, p. 707-710.

Additional information

Edit profile